Navigation Links
Mayo, UCSF team discovers genomic variant that increases risk of brain tumors
Date:8/26/2012

ROCHESTER, Minn. -- People who carry a "G" instead of an "A" at a specific spot in their genetic code have roughly a six-fold higher risk of developing certain types of brain tumors, a Mayo Clinic and University of California, San Francisco study has found. The findings, published online today in the journal Nature Genetics, could help researchers identify people at risk of developing certain subtypes of gliomas which account for about 20 percent of new brain cancers diagnosed annually in the U.S. and may lead to better surveillance, diagnosis and treatment.

Researchers still have to confirm whether the spot is the source of tumors, but if it's not, "it is pretty close," says senior author Robert Jenkins, M.D., Ph.D., a pathologist at the Mayo Clinic Cancer Center. "Based on our findings, we are already starting to think about clinical tests that can tell patients with abnormal brain scans what kind of tumor they have, just by testing their blood."

A few years ago, researchers began hunting for regions of the genome that might be associated with the development of gliomas. These groups observed a portion of chromosome 8 that contained single nucleotide polymorphisms or "SNPs" associated with brain tumors. Since then, Dr. Jenkins and Margaret Wrensch, Ph.D., professor of neurological surgery at the University of California, San Francisco, have been using a combination of sophisticated genomic techniques to search for the SNP causing brain tumors to form.

They honed in on seven candidates. One -- the SNP called rs55705857 -- confers a relative risk approaching that is seen with BRCA1, the breast cancer gene. Interestingly, this region was only found through the most laborious method used by the researchers, next generation sequencing, suggesting that experimental and mathematical shortcuts may miss such rare, highly potent gene variants, Dr. Jenkins says.

Drs. Jenkins and Wrensch found that having the "G" guanine version of this SNP -- rather than the more common "A" adenine version -- was strongly associated with slower growing gliomas.

"Being able to tell people that the mass in their brain is this type of tumor is actually good news, because it has a much better prognosis than other brain tumors," Dr. Jenkins says. "So what is it that predisposes people to develop less aggressive, but still lethal, gliomas? That makes understanding the function of this variant even more important."

As part of their work, the researchers compared the sequence of the gene variant throughout mammalian evolution and found that it has been conserved as far back as the platypus. Computer modeling indicated that the region may be a microRNA, a special kind of nucleic acid that controls the activity of genetic messages within cells. The modeling places the SNP within the functional part of the microRNA, suggesting that a change in genetic code from an A to a G could have significant consequences. The research team is investigating whether the microRNA actually exists, and what its functional implications might be.

"The altered microRNA might target tumor suppressor genes, it might activate a cancer gene, it might be involved in regulating the stability of the genome, or there might be something else going on altogether," Dr. Jenkins says. "One of the big challenges of the current genomic era is to assign functions to all these new gene variants."


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. IBN discovers human neural stem cells with tumor targeting ability
2. Rutgers team discovers novel approach to stimulate immune cells
3. UZH research team discovers the origins of key immune cells
4. Yale team discovers how stress and depression can shrink the brain
5. Following the genomic pathways to stop the spread of cancer
6. Genomic study of rare childrens cancer yields possible prognostic tool
7. Genetic variants, tobacco exposure and lung cancer risk
8. Moffitt Cancer Center study validates activity of rare genetic variant in glioma
9. Tuberculosis increases the risk of lung cancer mortality in the elderly
10. Bend Research increases hot-melt extrusion capacity
11. Despite less play, childrens use of imagination increases over 2 decades
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... on the world stage this week. A group of researchers and leaders from ... the Progress of Regenerative Medicine and Its Cultural Impact ” and receive the ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... accessories, is proud to partner with AquaShieldUSA, the country's oldest waterproof cast ... clinic and medical supply stores, the largest selection of daily, night, weatherproof and ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... the open availability of a new CDISC standard, Clinical Trial Registry (CTR) ... trials. This innovative standard will make it possible to build applications that ...
(Date:4/28/2016)... ... April 28, 2016 , ... Trinity ... Tobacco-Free Kids, a leading force in the fight to reduce tobacco use and ... policies that can help reduce tobacco use. The initiative brings together two organizations ...
(Date:4/28/2016)... ... 28, 2016 , ... In 2011, TIME magazine named Herr the “Leader of ... technology that marries human physiology with electromechanics. He continues that work as Director of ... of BionX , a leader in the field of prosthetic devices. , After ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)...  The blood testing market in China ... Information and The Freedonia Group in a recent report.  ... The healthcare research firm said that China ... stations and in improving testing at the provincial level.  ... Blood Testing Market in China , which ...
(Date:4/28/2016)... 2016 , Net Sales of $1.90 billion ... the prior year period, and an increase of 1.2% on ... EPS for the first quarter were $0.52 reported, a decrease ... an increase of 29.9% over the prior year period ... guidance for 2016 Zimmer Biomet Holdings, Inc. (NYSE ...
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ... on the development of oral drug delivery systems, announced today ... conference, presented by Joseph Gunnar & Co. LLC, ... York . Nadav Kidron , CEO of Oramed, ... Presentation Details:   PIONEERS 2016, presented by ...
Breaking Medicine Technology: